Design, synthesis and biological evaluation of novel β-caryophyllene derivatives as potential anti-cancer agents through the ROS-mediated apoptosis pathway†
IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics
{"title":"Design, synthesis and biological evaluation of novel β-caryophyllene derivatives as potential anti-cancer agents through the ROS-mediated apoptosis pathway†","authors":"Zhiwei Wang, Yang Chen, Anjie Huang, Hui Wen, Yetian Wu, Xingjun Xu, Zhongjing Qiao, Liangyu Chen, Yaopeng Zhao and Xinmiao Liang","doi":"10.1039/D4MD00951G","DOIUrl":null,"url":null,"abstract":"<p >As a top-three cancer in global incidence and mortality, colorectal cancer (CRC) urgently demands novel treatments. β-Caryophyllene (β-CP) and its derivatives, a class of sesquiterpenoids with broad anticancer potential, were structurally optimized in this study to enhance efficacy against CRC. Among the synthesized derivatives, <strong>AC-7</strong> exhibited potent cytotoxicity and selectivity in HT-29 cells (IC<small><sub>50</sub></small> = 3.09 μM, SI = 6.1), comparable to 5-fluorouracil (5-FU, IC<small><sub>50</sub></small> = 3.63 μM, SI = 0.4). Network pharmacology and gene enrichment analyses indicated that apoptosis, autophagy, ROS, and NF-κB were key downstream pathways of <strong>AC-7</strong>, which were later validated experimentally. <strong>AC-7</strong> arrested the cell cycle in the G0/G1 phase, promoted autophagy and apoptosis. ROS were identified as having a central role in regulating these related pathways. <em>In vivo</em> studies revealed the significant antitumor and DNA damage activity of <strong>AC-7</strong> in a nude mouse model. These findings suggest that <strong>AC-7</strong> is a promising candidate for anti-CRC therapy, acting through the ROS-mediated apoptosis pathway.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 7","pages":" 3174-3189"},"PeriodicalIF":3.5970,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/md/d4md00951g","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
As a top-three cancer in global incidence and mortality, colorectal cancer (CRC) urgently demands novel treatments. β-Caryophyllene (β-CP) and its derivatives, a class of sesquiterpenoids with broad anticancer potential, were structurally optimized in this study to enhance efficacy against CRC. Among the synthesized derivatives, AC-7 exhibited potent cytotoxicity and selectivity in HT-29 cells (IC50 = 3.09 μM, SI = 6.1), comparable to 5-fluorouracil (5-FU, IC50 = 3.63 μM, SI = 0.4). Network pharmacology and gene enrichment analyses indicated that apoptosis, autophagy, ROS, and NF-κB were key downstream pathways of AC-7, which were later validated experimentally. AC-7 arrested the cell cycle in the G0/G1 phase, promoted autophagy and apoptosis. ROS were identified as having a central role in regulating these related pathways. In vivo studies revealed the significant antitumor and DNA damage activity of AC-7 in a nude mouse model. These findings suggest that AC-7 is a promising candidate for anti-CRC therapy, acting through the ROS-mediated apoptosis pathway.
期刊介绍:
Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry.
In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.